Track record · closed signal

Halozyme Therapeutics, Inc. (HALO) — closed signal from September 22, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 21, 2025.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted
$78.64 Published $94.37 Target $67.35 Window close $79.50 Peak
$75.00 – $77.00Entry zone — fair-value band
$78.64Published — price the day we called it
$94.37Target — the price the thesis aimed for
$79.50Peak — highest point inside the window, not a realized return
$67.35Window close — end-of-window price, context only

What happened

Partial

Reached 6% of the predicted growth at its peak, without hitting the target.

Peak price
$79.50
peak on September 23, 2025 — not a realized return
Peak gain
+1.1%
peak, from the publication price
Window close
$67.35
end-of-window price, context only
Days to target
—
Window
September 22, 2025 – December 21, 2025

The thesis — published September 22, 2025

Predicted growth
+20%
over the measurement window
Target price
$94.37
the price the thesis aimed for
Entry zone
$75.00 – $77.00
the fair-value band we waited for
Price at publication
$78.64
published September 22, 2025
Confidence
74%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Halozyme looks solid and investors seem positive. Recent nods, like a top rating from Zacks (9/19) and Morgan Stanley lifting its target to $80 (8/18), back the idea that royalties from its ENHANZE technology can keep growing. The recent average price is trending up, while short-term momentum is a bit soft, which often happens during a pause. Plan: buy on dip days and look for a clear move back over the $80 area in the next 0-3 months.

Primary drivers

  • More partner drugs using ENHANZE can lift steady royalty income
  • Analyst upgrades and higher targets help keep buyers interested
  • Recent average price rising, brief pause likely before next leg
  • Light cost structure helps profits scale as sales royalties grow

How it played out

HALO: target was not reached

Lyra published HALO at $78.64 on 2025-09-22 with 20% expected growth. The thesis pointed to more partner drugs using ENHANZE, analyst upgrades and higher targets, a rising recent average price after a brief pause, and a light cost structure that could help profits scale as royalty sales grew.

Inside the window, HALO peaked at $79.50 on 2025-09-23, with a 1.1% peak gain. It stayed below the $94.37 target and never got there. By 2025-12-21, it ended at $67.35. The thesis missed on price action.

What happened during the window

On November 3, 2025, Halozyme reported third-quarter results, according to Investor's Business Daily. The article said profit was $1.72 a share, revenue was $354 million, and royalty revenue was $236 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals